Clinical Trials Browser

Resectable Intrahepatic Cholangiocarcinoma

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

Biliary Tract Neoplasms

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Pancreatic Neoplasms

Cholangiocarcinoma

Carcinoma, Hepatocellular

Biliary Tract Neoplasms

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Advanced Biliary Tract Carcinoma

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

Colorectal Neoplasms

Gastroesophageal Adenocarcinoma

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Adenocarcinoma Of Esophagus, Biliary Tract Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

Carcinoma, Hepatocellular, Cholangiocarcinoma

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Carcinoma, Hepatocellular

Fibrolamellar hepatocellular carcinoma, Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Advanced Biliary Tract Cancer

Adenocarcinoma Of Esophagus, Carcinoma, Hepatocellular, Stomach Neoplasms, Colorectal Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms

Adenocarcinoma, Stomach Neoplasms

Biliary Tract Neoplasms

Carcinoma, Hepatocellular, Liver Cirrhosis

Carcinoma, Hepatocellular

Hepatobiliary Cancers

Biliary Tract Neoplasms, Cholangiocarcinoma

Carcinoma, Hepatocellular

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Cholangiocarcinoma

Carcinoma, Hepatocellular

Cholangiocarcinoma

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Liver Neoplasms

Carcinoma, Hepatocellular

Cholangiocarcinoma

Esophageal Neoplasms

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Biliary Tract Neoplasms, Gallbladder Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Clinical Trials

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

IMFINZI-subQ

DESTINY-BTC01

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

REFINE-IO

SLIDE-HCC

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

TACTIC

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

AB02

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

HAIC-quad

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

DG-03

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

ALICE

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

CAMILLA

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

TREMENDOUS-2

LIVER-R

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

ZENOBIA

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Proton-STRIDE

SIRT With Tremelimumab and Durvalumab for Resectable HCC

LIVIGNO-2

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

PALEO

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Photon-STRIDE

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

RUGB

DUMELEP

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC